From SEC Filing of Todays RNS15 Apr 2019 12:38
We also believe that iclaprim could have potential in indications beyond ABSSSI. This includes HABP, including ventilator associated bacterial pneumonia (VABP), as there is a major unmet need for new therapies in this indication, which has a high mortality rate. A Phase 2 trial evaluating iclaprim in patients with HABP has been successfully completed and a Phase 3 trial is planned to start, subject to additional funding and likely with a partner.